A recent study published in the Journal of Clinical Oncology discusses the findings of an indirect treatment comparison of nivolumab plus relatlimab and nivolumab plus ipilimumab using data from previous trials in patients with advanced melanoma.
Question 1 of 5
Which immune checkpoint protein does relatlimab target?
